Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Zura Bio Limited (ZURA : NSDQ)

• Company Description    Zura Bio Limited is a clinical-stage biotechnology company advancing primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease and asthma. Zura Bio Limited, formerly known as JATT Acquisition Corp, is headquartered in London, UK. Number of Employees: 30

• Price / Volume Information    Yesterday's Closing Price: $5.24 Daily Weekly Monthly 20 Day Moving Average: 517,636 shares Shares Outstanding: 65.02 (millions) Market Capitalization: $340.72 (millions) Beta: 0.20 52 Week High: $5.62 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 34.70% 34.93% 12 Week 16.19% 14.31% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1489 W. Warm Springs Road Suite 110 - Henderson,NV 89014 USA ph: 702-825-9872 fax: - ir@zurabio.com https://zurabio.com

• General Corporate Information    Officers Robert Lisicki - Chief Executive Officer Amit Munshi - Chairman Verender Badial - Chief Financial Officer Someit Sidhu - Director Steve Schoch - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G9TY5A101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/24/26 Share - Related Items Shares Outstanding: 65.02 Most Recent Split Date: (:1) Beta: 0.20 Market Capitalization: $340.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 19.23% vs. Previous Quarter: -23.53% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -51.09 06/30/25 - -49.11 ROA 12/31/25 - - 09/30/25 - -41.05 06/30/25 - -40.06 Current Ratio 12/31/25 - - 09/30/25 - 5.58 06/30/25 - 8.40 Quick Ratio 12/31/25 - - 09/30/25 - 5.58 06/30/25 - 8.40 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 1.69 06/30/25 - 2.05 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©